. 2022 Feb 21;14(2):444. doi: 10.3390/v14020444

Table 2.

Outcomes after 6-month treatment.

Variables	Treatment	Baseline	Follow-Up	p-Value (Baseline vs. Follow-Up)	p-Value (Treated vs. Placebo at Follow-Up)
LVEF, %	IFN-ß total	51.6 ± 14.1	61.0 ± 17.5	0.03	0.14
LVEF, %	Placebo	52.00 ± 20.0	42.00 ± 17.9	0.65	0.14
NT-proBNP, pg/mL	IFN-ß total	548 ± 204	319 ± 59	0.001	0.004
NT-proBNP, pg/mL	Placebo	514 ± 276	562 ± 202	0.53	0.004
NYHA class (I/II/III/IV)	IFN-ß total	0/5/8/0	7/5/1/0	0.003	0.21
NYHA class (I/II/III/IV)	Placebo	0/2/3/0	1/1/3/0	0.9	0.21

Note: INF-ß: Interferon beta-1b total (4 × 10⁶ IU + 8 × 10⁶ IU). LVEF: left ventricular ejection fraction; NT-proBNP: N terminal pro brain natriuretic peptide; NYHA: New York Heart Association functional class. NYHA is a graded class of functional capacity. Class I indicates no symptoms or limitations in ordinary physical activity; class II, dyspnea with moderate exertion; class III, dyspnea with mild exertion; and class IV, dyspnea at rest. The data are presented as mean ± standard deviation.